Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present its groundbreaking pharmacokinetic (PK) study at the ADLM 2025 Clinical Lab Expo in Chicago. The study underscores the efficacy of the company's Intelligent Fingerprinting Drug Screening System, demonstrating that fingerprint sweat can accurately reflect codeine levels comparable to those found in blood and saliva. This advancement positions the system as a viable, non-invasive alternative for drug screening in various settings, including workplaces, clinical environments, and justice systems.
Daniel Brown, Head of Clinical Affairs at INBS, will present the findings during the Poster Hall sessions, offering insights into how this technology could transform drug testing protocols. With its portable design, the system promises quick results in under ten minutes, making it an invaluable tool for industries where safety is paramount. The company's technology is already making waves internationally, with over 450 accounts across 24 countries, catering to sectors such as construction, manufacturing, and transport.
The presentation at the ADLM 2025 Clinical Lab Expo marks a significant milestone for INBS, as it continues to expand the applications of its fingerprint sweat analysis technology. Beyond drug screening, the potential for broader diagnostic uses could revolutionize how medical testing is conducted, offering a hygienic, cost-effective, and dignified solution for patients and professionals alike.
